Genetic capsules: the medicine of the future developed by Claudio Hetz

Genetic capsules: the medicine of the future developed by Claudio Hetz

The Chilean scientist seeks to combat various neurodegenerative, as the ALS, Parkinson's and Alzheimer's diseases, attacking damaged through a gene encapsulated proteins.

The engineer in Molecular biotechnology of the University of Chile, Claudio Hetz, presented an innovative method to combat diseases that neurons degenerate. As explained by the scientist in the future Congress the treatment focuses on attacking damaged proteins.

The research led by the director of the Institute of neuroscience in biomedicine and researcher at the center of Gerociencia, Mental health, and metabolism (GERO) It aims to improve the quality of aging in order to "help the cells to repair the damage of proteins which is the cause of [Alzheimer's disease, als and Parkinson's]".

As the doctor said, as these diseases are disorders that "only manifested when we age".

"All brain diseases have the same cause, the deterioration of proteins" explained Hetz who XBP1, which allows you to reprogram cells, combats these diseases through the use of the gene.

In conversation with Emol indicated that "what we are doing is to deliver the correct gene, which produces this protein, which would attack a drug". Despite that, the expert pointed out that "the problem at the moment is still the industrial production of" these biological capsules which deliver the therapeutic gene, are very expensive to produce".

The advancement presented by the researcher has the quality of "once the gene is delivered to a cell, still there's lifetime and no longer have to do more treatment".

The "medicine of the future" from Chile

"We have been trying this gene therapy in different diseases and we send a patent application parallel, at the moment we are in discussions with" a group of investment in Australia that we could perhaps license this patent and they develop at the chemical level for future marketing,"said the scientist.

On the other hand, on the progress and the purpose of these studies Hetz said: "We are generating more intellectual property from Chile. We don't want to do clinical trials, it is not my purpose. My purpose is to generate experimental therapeutic strategies that generate intellectual property".

In addition the researcher added that his team is interdisciplinary. "40 people work in my lab, is divided into 4 groups, led by various young researchers." There is a block that studies ELA, another alzheimer, parkinson, and others that make more fundamental sciences“.

The scientist concluded that this advance "clearly it is the medicine of the future".